Ocular Therapeutix (OCUL) Other Accumulated Expenses (2013 - 2026)

Ocular Therapeutix has reported Other Accumulated Expenses for 14 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 4.19% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 4.19% YoY), and the FY2025 full-year result was $1.9 million, down 6.76% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.7 million, down from $1.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.1 million in Q4 2024, with the low at $1.1 million in Q2 2022.
• Average Other Accumulated Expenses over 5 years is $1.6 million, with a median of $1.6 million recorded in 2024.
• Year-over-year, Other Accumulated Expenses surged 61.58% in 2024 and dropped 10.53% in 2025.
• Tracing OCUL's Other Accumulated Expenses over 5 years: stood at $1.2 million in 2022, then increased by 24.19% to $1.5 million in 2023, then jumped by 34.75% to $2.1 million in 2024, then slipped by 6.76% to $1.9 million in 2025, then slipped by 13.0% to $1.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.7 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison